The following care pathways are scheduled for an update in July 2015 in response to changes in the evidence base:

  1. Anaemia: Medicines and Healthcare Products Regulatory Agency (MHRA) Drug Safety Update ’Rienso (Ferumoxytol) – On-going review of global post-marketingreports of serious hypersensitivity reactions’
  2. Bipolar disorder: NICE CG185 ‘Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care’
  3. Bladder cancer: NICE NG2 ‘Bladder cancer: diagnosis and management’
  4. Brain tumour: European Society for Medical Oncology (ESMO) guideline, ‘High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’
  5. Chronic obstructive pulmonary disease: MHRA drug safety update ‘Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial’
  6. Colorectal cancer: NICE CG131 ‘Colorectal cancer: The diagnosis and management of colorectal cancer’
  7. Community-acquired pneumonia: NICE CG191 ‘Pneumonia: Diagnosis and management of community- and hospital-acquired pneumonia in adults’
  8. Contraception: Faculty of Sexual & Reproductive Healthcare Statement ‘Venous Thromboembolism (VTE) and Hormonal Contraception’
  9. Deep vein thrombosis: NICE TA327 ‘Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism’
  10. Depression in adults: NICE CG192 ‘Antenatal and postnatal mental health: clinical management and service guidance’
  11. Depression in children and adolescents: NICE CG28 ‘Depression in children and young people: Identification and management in primary, community and secondary care’
  12. Diabetes in pregnancy: NICE NG3 ‘Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period’
  13. Dyslipidaemia: NICE CG181 ‘Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease’
  14. Gastro-oesophageal reflux disease (GORD) in children and adolescents: NICE guideline NG1 ‘Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people ‘
  15. Headache: Medicines and Healthcare Products Regulatory Agency (MHRA) Drug Safety update Domperidone: new recommendations to minimise the cardiac risks
  16. Irritable bowel syndrome: NICE CG61 ‘Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care’
  17. Kidney stones: European Association of Urology (EAU) ‘Guidelines on urolithiasis’
  18. Knee pain: Royal College of Surgeons guideline ‘RCS Commissioning guide: painful osteoarthritis of the knee’
  19. Lymphoma: European Society of Medical Oncology (ESMO) ‘Hodgkin’s Lymphoma: ESMO Clinical Practice Guidelines’
  20. Meticillin-resistant Staphylococcus aureus (MRSA): Department of Health guideline ‘Implementation of modified admission MRSA screening’
  21. Obesity in adults: NICE CG189 ‘Obesity: identification, assessment and management of overweight and obesity in children, young people and adults’
  22. Obesity in children: NICE CG189 ‘Obesity: identification, assessment and management of overweight and obesity in children, young people and adults’
  23. Osteoporosis: MHRA drug safety update ‘Denosumab: minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia—updated recommendations’
  24. Perinatal mental health: NICE CG192 ‘Antenatal and postnatal mental health: clinical management and service guidance’
  25. Postnatal care: NICE CG37 ‘postnatal care’
  26. Pulmonary embolism: European Society of Cardiology (ESC)‘2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism’
  27. Refusal of treatment: Department of Health ‘Code of practice: Mental Health Act 1983’
  28. Ulcerative colitis: NICE TA329 ‘Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)’

Our Clinical Editorial team continuously monitor the underlying evidence of pathways and also work with external stakeholders to ensure pathways are practice-informed. As such, our publications are subject to change at short notice. For the latest information please contact us.